Back to Report Store Home

Optic Nerve Disorders Drug Development Pipeline Review, 2018

  • Published: Oct-2018
  • Report Code: GBIHC049IDB
  • Report Format: pdf

Description

List of Figures

Figure 1: Number of Products under Development for Optic Neuropathy

Figure 2: Number of Products under Development by Companies, Optic Neuropathy

Figure 3: Number of Products under Development for Glaucoma

Figure 4: Number of Products under Development by Companies, Glaucoma

Figure 5: Number of Products under Development by Universities/Institutes, Glaucoma

Figure 6: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 7: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 8: Number of Products under Development for Optic Neuritis

Figure 9: Number of Products under Development by Companies, Optic Neuritis

Figure 10: Number of Products by Top 10 Targets, Optic Neuropathy

Figure 11: Number of Products by Stage and Top 10 Targets, Optic Neuropathy

Figure 12: Number of Products by Top 10 Mechanism of Actions, Optic Neuropathy

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Optic Neuropathy

Figure 14: Number of Products by Routes of Administration, Optic Neuropathy

Figure 15: Number of Products by Stage and Routes of Administration, Optic Neuropathy

Figure 16: Number of Products by Molecule Types, Optic Neuropathy

Figure 17: Number of Products by Stage and Molecule Types, Optic Neuropathy

Figure 18: Number of Products by Top 10 Targets, Glaucoma

Figure 19: Number of Products by Stage and Top 10 Targets, Glaucoma

Figure 20: Number of Products by Top 10 Mechanism of Actions, Glaucoma

Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Glaucoma

Figure 22: Number of Products by Routes of Administration, Glaucoma

Figure 23: Number of Products by Stage and Routes of Administration, Glaucoma

Figure 24: Number of Products by Top 10 Molecule Types, Glaucoma

Figure 25: Number of Products by Stage and Top 10 Molecule Types, Glaucoma

Figure 26: Number of Products by Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 27: Number of Products by Stage and Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 28: Number of Products by Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 29: Number of Products by Stage and Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 30: Number of Products by Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 31: Number of Products by Stage and Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 32: Number of Products by Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 33: Number of Products by Stage and Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)

Figure 34: Number of Products by Targets, Optic Neuritis

Figure 35: Number of Products by Stage and Targets, Optic Neuritis

Figure 36: Number of Products by Mechanism of Actions, Optic Neuritis

Figure 37: Number of Products by Stage and Mechanism of Actions, Optic Neuritis

Figure 38: Number of Products by Routes of Administration, Optic Neuritis

Figure 39: Number of Products by Stage and Routes of Administration, Optic Neuritis

Figure 40: Number of Products by Molecule Types, Optic Neuritis

Figure 41: Number of Products by Stage and Molecule Types, Optic Neuritis

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards